Cancer
Neoplasm of Uncertain Histogenesis
CI-CAN-00000034Explore in graph →
Non-malignant20,280 active trials259 approved drugs3,813 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer
CI-CAN-00000034Explore in graph →
Clinical trials
91,351 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06324357 | Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread | recruiting | Phase 1 / Phase 2 | 768 | Boehringer IngelheimINDUSTRY | 10 | Sep 30, 2026 | clinicaltrials |
| NCT06328361 | Nordic ORgan Preservation Pilot Approach Nonrandomised Single-Arm Trial for Non-Operative Management of Rectal Cancer(NORPPA-1) | recruiting | N/A | 200 | Tampere University HospitalOTHER | 2 |
| Sep 30, 2026 |
| clinicaltrials |
| NCT06352684 | Effectiveness of CadAI-B for Breast | completed | — | 1,000 | BeamWorks Inc.INDUSTRY | 1 | Sep 30, 2026 | clinicaltrials |
| NCT06394570 | Enfortumab Vedotin and Stereotactic Radiation for Localized Bladder Cancer(STAR-EV) | recruiting | Phase 1 / Phase 2 | 19 | University of Texas Southwestern Medical CenterOTHER | 1 | Sep 30, 2026 | clinicaltrials |
| NCT06406465 | A UGT1A1 Genotype-Directed Study of Belinostat Pharmacokinetics and Toxicity | recruiting | Phase 2 | 60 | National Cancer Institute (NCI)NIH | 1 | Sep 30, 2026 | clinicaltrials |
| NCT06422806 | Measuring if Immunotherapy Plus Chemotherapy is Better Than Chemotherapy Alone for Patients With Aggressive Poorly Differentiated Sarcomas | recruiting | Phase 3 | 365 | National Cancer Institute (NCI)NIH | 3 | Sep 30, 2026 | clinicaltrials |
| NCT06423170 | A Single-arm Phase II Clinical Study of the Efficacy and Safety of Camrelizumab Combined With GEMOX for Unresectable GBCs | recruiting | Phase 2 | 37 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityOTHER | 1 | Sep 30, 2026 | clinicaltrials |
| NCT06423326 | Gemcitabine, Cisplatin and Nab-Paclitaxel as Neoadjuvant Treatment for Patients With Resectable or Borderline Resectable Pancreatic Cancer | recruiting | Phase 2 | 36 | Georgetown UniversityOTHER | 1 | Sep 30, 2026 | clinicaltrials |
| NCT06487481 | Study of Preoperative Radiation Therapy in Participants With Resectable Recurrent Abdominal Adrenocortical Carcinoma | recruiting | Phase 1 | 32 | National Cancer Institute (NCI)NIH | 1 | Sep 30, 2026 | clinicaltrials |
| NCT06492954 | Atezolizumab in Combination With Stereotactic Body Radiation Therapy (SBRT) and Surgery for Relapsed Osteosarcoma(AflacST2301) | recruiting | Phase 1 | 12 | Emory UniversityOTHER | 1 | Sep 30, 2026 | clinicaltrials |
| NCT06510530 | Astragalus for Symptomatic Alleviation in High-grade Lymphoma | not yet recruiting | Phase 3 | 60 | Bnai Zion Medical CenterOTHER_GOV | 1 | Sep 30, 2026 | clinicaltrials |
| NCT06515249 | Integrative Therapies in Multiple Myeloma | recruiting | N/A | 300 | Bnai Zion Medical CenterOTHER_GOV | 1 | Sep 30, 2026 | clinicaltrials |
| NCT06524544 | A Study Comparing the Combination of Pembrolizumab and Sacituzumab Govitecan-hziy Versus Standard of Care in the Treatment of Advanced Urothelial Cancer | recruiting | Phase 3 | 320 | National Cancer Institute (NCI)NIH | 1 | Sep 30, 2026 | clinicaltrials |
| NCT06541405 | Safety and Efficacy of NK520 to Treat Pediatric Relapsed/Refractory Acute Myeloid Leukemia | terminated | Early Phase 1 | 2 | Base Therapeutics (Shanghai) Co., Ltd.INDUSTRY | 1 | Sep 30, 2026 | clinicaltrials |
| NCT06541444 | Safety and Efficacy of NK520 to Treat Relapsed/Refractory Acute Myeloid Leukemia | terminated | Early Phase 1 | 2 | Base Therapeutics (Shanghai) Co., Ltd.INDUSTRY | 1 | Sep 30, 2026 | clinicaltrials |
| NCT06565052 | The Impact of PReOPerative Exercise and NutritionaL Optimization on Perioperative Outcomes for Patients Undergoing Treatment for Rectal Cancer: The PROPEL Trial | recruiting | N/A | 40 | Dana-Farber Cancer InstituteOTHER | 1 | Sep 30, 2026 | clinicaltrials |
| NCT06589804 | Testing the Addition of Anti-Cancer Drug, Cetuximab, to Standard of Care Treatment (Pembrolizumab) for Returning or Spreading Head and Neck Cancer After Previous Treatment | recruiting | Phase 3 | 158 | National Cancer Institute (NCI)NIH | 1 | Sep 30, 2026 | clinicaltrials |
| NCT06630429 | A Pilot Study of Blood-based Biomarkers for Response to Immune Checkpoint Inhibitors | active not recruiting | — | 100 | Ohio State University Comprehensive Cancer CenterOTHER | 1 | Sep 30, 2026 | clinicaltrials |
| NCT06630780 | Reduction of Postoperative Radiotherapy in Head and Neck Squamous Cell Carcinoma(REPORT-HNSCC) | active not recruiting | N/A | 50 | Sun Yat-sen UniversityOTHER | 1 | Sep 30, 2026 | clinicaltrials |
| NCT06661915 | A Randomized Study of ASTX727 With or Without Iadademstat in Advanced Myeloproliferative Neoplasms (MPNs) | recruiting | Phase 2 | 78 | National Cancer Institute (NCI)NIH | 1 | Sep 30, 2026 | clinicaltrials |
| NCT06674863 | Addressing Health Literacy With a Tailored Survivorship Care Plan | recruiting | N/A | 150 | Emory UniversityOTHER | 1 | Sep 30, 2026 | clinicaltrials |
| NCT06694454 | Neoadjuvant Inhaled Azacytidine With Platinum-Based Chemotherapy and Durvalumab (MEDI4736) - a Combined Epigenetic-Immunotherapy (AZA-AEGEAN) Regimen for Operable Early-Stage Non-Small Cell Lung Cancer (NSCLC) | suspended | Phase 1 / Phase 2 | 60 | National Cancer Institute (NCI)NIH | 1 | Sep 30, 2026 | clinicaltrials |
| NCT06750458 | Dapagliflozin Versus Dexamethasone Role in Pre-operative Management of Non- Diabetic Brain Tumor Patients | completed | Phase 3 | 75 | Tanta UniversityOTHER | 1 | Sep 30, 2026 | clinicaltrials |
| NCT06764485 | A Study to Compare the Efficacy and Safety of BMS-986365 Versus the Investigator's Choice of Therapy in Participants With Metastatic Castration-resistant Prostate Cancer(rechARge) | active not recruiting | Phase 3 | 960 | CelgeneINDUSTRY | 26 | Sep 30, 2026 | clinicaltrials |
| NCT06765109 | Neladalkib (NVL-655) for TKI-naive Patients With Advanced ALK-Positive NSCLC(ALKAZAR) | recruiting | Phase 3 | 450 | Nuvalent Inc.INDUSTRY | 29 | Sep 30, 2026 | clinicaltrials |
| NCT06770582 | Testing the Addition of the Immunotherapy Drug, Pembrolizumab, to Radiation Therapy Compared to the Usual Chemotherapy Treatment During Radiation Therapy for Bladder Cancer, PARRC Trial | recruiting | Phase 2 | 160 | National Cancer Institute (NCI)NIH | 2 | Sep 30, 2026 | clinicaltrials |
| NCT06806852 | A Study to Test Whether Treatment With BI 770371 in Combination With Pembrolizumab With or Without Cetuximab Helps People With Head and Neck Cancer Compared With Pembrolizumab Alone | active not recruiting | Phase 1 | 91 | Boehringer IngelheimINDUSTRY | 22 | Sep 30, 2026 | clinicaltrials |
| NCT06815432 | GPC-3 CAR T CELLS FOR Recurrent GPC-3 Positive Glioblastoma | recruiting | Phase 1 | 27 | Baylor College of MedicineOTHER | 1 | Sep 30, 2026 | clinicaltrials |
| NCT06826014 | TREC@TAMU Cancer Prevention Registry and Repository | recruiting | — | 2,500 | Texas A&M UniversityOTHER | 1 | Sep 30, 2026 | clinicaltrials |
| NCT06855628 | Assessment of Novel Metabolic Imaging Modalities as A Predictor Of Therapeutic EfficacyiIn Glioblastoma (GBM) | completed | Phase 2 | 2 | Stanford UniversityOTHER | 1 | Sep 30, 2026 | clinicaltrials |
| NCT06876142 | Combination Therapy (Mirdametinib and Sirolimus) for RAS Mutated Relapsed Refractory Multiple Myeloma | suspended | Phase 1 / Phase 2 | 54 | National Cancer Institute (NCI)NIH | 1 | Sep 30, 2026 | clinicaltrials |
| NCT06890273 | NIS to Examine the Effectiveness and Safety of Durvalumab and Olaparib in Patients With Endometrial Cancer (DUOLife)(DUOLife) | recruiting | — | 150 | AstraZenecaINDUSTRY | 1 | Sep 30, 2026 | clinicaltrials |
| NCT06904066 | Autologous T Cells Transduced With Retroviral Vectors Expressing TCRs for Participant-specific Neoantigens in Patients With Hematologic Malignancies | recruiting | Phase 1 | 86 | National Cancer Institute (NCI)NIH | 1 | Sep 30, 2026 | clinicaltrials |
| NCT06917911 | Testing the Addition of Venetoclax or Gemtuzumab Ozogamicin (GO) to Usual Treatment Regimen (Cytarabine and Daunorubicin, "7+3") for Core Binding Factor Acute Myeloid Leukemia (CBF-AML) to Improve Response (A MYELOMATCH Treatment Trial) | recruiting | Phase 2 | 162 | National Cancer Institute (NCI)NIH | 2 | Sep 30, 2026 | clinicaltrials |
| NCT06918002 | Elranatamab/Lenalidomide Consolidation and/or Elranatamab Maintenance Versus Standard of Care After D-VRd Induction in Transplant-eligible NDMM Patients(ElLen) | recruiting | Phase 3 | 824 | Intergroupe Francophone du MyelomeNETWORK | 2 | Sep 30, 2026 | clinicaltrials |
| NCT06991738 | 177Lu-DOTA-EB-TATE in Adult Patients With Metastatic, Radioactive Iodine Non-Responsive Oncocytic (Hurthle-Cell) Thyroid Cancer | not yet recruiting | Phase 1 / Phase 2 | 18 | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)NIH | 1 | Sep 30, 2026 | clinicaltrials |
| NCT07005297 | Clinical Genetics Branch Eligibility Screening Survey | not yet recruiting | — | 1,000 | National Cancer Institute (NCI)NIH | 1 | Sep 30, 2026 | clinicaltrials |
| NCT07015242 | A Study of the Efficacy and Safety of Lisocabtagene Maraleucel (Liso-cel) as First-Line Therapy in Adults With Transplant-Ineligible Primary Central Nervous System Lymphoma | recruiting | Phase 2 | 65 | Juno Therapeutics, Inc., a Bristol-Myers Squibb CompanyINDUSTRY | 3 | Sep 30, 2026 | clinicaltrials |
| NCT07023887 | Prospective Study of EXErcise Regimens After Treatment for Breast Cancer for Hypertrophy and Conditioning(EXERT-BCHC) | recruiting | — | 15 | Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute)OTHER | 1 | Sep 30, 2026 | clinicaltrials |
| NCT07042295 | Treatment With Amivantamab and Hyaluronidase or Cetuximab for Advanced Skin Cancer in People With a Weakened Immune System | recruiting | Phase 2 | 86 | National Cancer Institute (NCI)NIH | 1 | Sep 30, 2026 | clinicaltrials |
| NCT07061964 | Combining Immunotherapy and Radiation Therapy to Help Patients Avoid Bladder Removal After Treatment Shrinks Muscle Invasive Bladder Cancer, BRIGHT Trial | recruiting | Phase 2 | 111 | National Cancer Institute (NCI)NIH | 1 | Sep 30, 2026 | clinicaltrials |
| NCT07061977 | Induction Pembrolizumab and Chemotherapy Followed by Pembrolizumab Before Chemoradiation and Pembrolizumab Maintenance Compared to Standard Chemoradiation With Pembrolizumab Followed by Pembrolizumab Maintenance in High-Risk Cervical Cancer | recruiting | Phase 3 | 336 | National Cancer Institute (NCI)NIH | 2 | Sep 30, 2026 | clinicaltrials |
| NCT07085091 | A First in Human Study of ALX2004 With Advanced or Metastatic Selected Solid Tumors | recruiting | Phase 1 | 170 | ALX Oncology Inc.INDUSTRY | 1 | Sep 30, 2026 | clinicaltrials |
| NCT07137793 | Clinical Study to Evaluate The Cardioprotective Effect of Pentoxifylline Against Doxorubicin Induced Cardiotoxicity in Breast Cancer Patients(PTX / BC) | completed | Phase 2 | 46 | Tanta UniversityOTHER | 1 | Sep 30, 2026 | clinicaltrials |
| NCT07143604 | A Study to Investigate the Effects of AZD0901 Monotherapy in Adult Participants With 2L+ Advanced or Metastatic Gastric or GEJ Adenocarcinoma Expressing CLDN18.2(GAMBIT) | active not recruiting | Phase 2 | 33 | AstraZenecaINDUSTRY | 1 | Sep 30, 2026 | clinicaltrials |
| NCT07189871 | 177Lu-BetaBart in Patients With Relapsed/Refractory, Locally Advanced Inoperable, or Metastatic Solid Tumors(BetaBart) | recruiting | Phase 1 / Phase 2 | 61 | Radiopharm Theranostics, LtdINDUSTRY | 1 | Sep 30, 2026 | clinicaltrials |
| NCT07198074 | Testing the Addition of an Antiangiogenic Drug (Bevacizumab) to Chemotherapy (Carboplatin and Paclitaxel) Combined With Immunotherapy (Pembrolizumab) for pMMR, TP53 Mutated Endometrial Cancer | recruiting | Phase 3 | 255 | National Cancer Institute (NCI)NIH | 1 | Sep 30, 2026 | clinicaltrials |
| NCT07218250 | A Study of a One-Time Counseling Session to Help Reduce Depression, Anxiety, and Distress in People With Cancer | recruiting | N/A | 26 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Sep 30, 2026 | clinicaltrials |
Data updated 3 hours agoSource updated Sep 30, 2026source: clinicaltrials